NCT00949949View on ClinicalTrials.gov

Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Cholangiocarcinoma of the GallbladderLocalized Gallbladder CancerUnresectable Gallbladder CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

everolimus

Given PO

DRUG

gemcitabine hydrochloride

Given IV

DRUG

cisplatin

Given IV

Trial Locations (3)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00949949 - Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy | Biotech Hunter | Biotech Hunter